Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Seagate Technology Holdings PLC (STX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Seagate Technology Holdings PLCTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Seagate Technology Holdings PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Seagate Technology Holdings PLC trades at $879.04 (market cap $185.97B), while State Street SPDR S&P Biotech ETF trades at $159.25. The key difference: Seagate Technology Holdings PLC pays a 0.36% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.

STXXBI
Market Cap
$185.97B
Sector
TechnologyBroad Market / Factor
52-Week High
$1.09K$164.28
52-Week Low
$154.43$86.92
Enterprise Value
$188.12B
Dividend Yield
0.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Seagate Technology Holdings PLC

Seagate Technology (STX) trades at $879.11, up 9.79% in 24 hours, reflecting strong momentum driven by AI storage demand. The stock shows a neutral technical signal with support near $803 and resistance at $833. Recent earnings beats and a projected 2026 net income margin of 26.1% highlight robust fundamentals, though elevated valuation ratios like a P/E of 59.03 warrant caution. Positive analyst sentiment, with 55% buy ratings and a consensus price target of $1,130, underscores growth optimism amid AI-driven data center expansion.

Outlook: STX benefits from AI storage tailwinds and disciplined supply, but high debt and valuation pose risks. The stock offers growth potential if execution continues, yet volatility from memory market cycles and competitive pressures requires monitoring. Investor focus remains on HAMR technology adoption and sustained margin improvement.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Seagate Technology Holdings PLC

Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital

Read more on STX

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI